Skip to main content
Erschienen in: International Journal of Hematology 3/2023

31.03.2023 | Case Report

Severe systemic inflammation mimicking TAFRO syndrome following COVID-19

verfasst von: Misato Tane, Hideki Kosako, Hiroki Hosoi, Kayoko Tabata, Takayuki Hiroi, Kosuke Osawa, Ryuta Iwamoto, Shogo Murata, Toshiki Mushino, Shin-Ichi Murata, Shin-Ichi Araki, Takao Fujii, Takashi Sonoki

Erschienen in: International Journal of Hematology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

TAFRO syndrome is a rare systemic inflammatory disease. Its pathogenesis mainly involves excessive cytokine secretion and autoimmune dysfunction. Although its etiology is unclear, some viral infections have been reported to cause it. Here, we report a case of severe systemic inflammation mimicking TAFRO syndrome that arose after COVID-19. A 61-years-old woman suffered from a continuous fever, ascites, and edema after contracting COVID-19. She developed progressive thrombocytopenia, renal failure, and elevated C-reactive protein levels. She was tentatively diagnosed with multisystem inflammatory syndrome in adults (MIS-A) and received steroid pulse therapy. However, she exhibited worsening fluid retention and progressive renal failure, which are not typical of MIS-A. A bone marrow examination showed reticulin myelofibrosis and an increased number of megakaryocytes. Although a definitive diagnosis of TAFRO syndrome was not made according to current diagnostic criteria, we determined that her symptoms were clinically consistent with those of TAFRO syndrome. Combination therapy, including steroid pulse therapy, plasma exchange, rituximab, and cyclosporine, improved her symptoms. There are pathological similarities between hyperinflammation that arises after COVID-19 and TAFRO syndrome in terms of the associated cytokine storms. COVID-19 may have triggered the development of systemic inflammation mimicking TAFRO syndrome in this case.
Literatur
1.
Zurück zum Zitat Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–8.CrossRefPubMed Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–8.CrossRefPubMed
4.
5.
Zurück zum Zitat Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975–83.CrossRefPubMed Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975–83.CrossRefPubMed
6.
Zurück zum Zitat Simons M, Apor E, Butera JN, Treaba DO. TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol. 2016;2016:4703608.PubMedPubMedCentral Simons M, Apor E, Butera JN, Treaba DO. TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol. 2016;2016:4703608.PubMedPubMedCentral
7.
Zurück zum Zitat Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017–32.CrossRefPubMed Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017–32.CrossRefPubMed
8.
Zurück zum Zitat Nazerian Y, Ghasemi M, Yassaghi Y, Nazerian A, Hashemi SM. Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: molecular pathways and potential therapeutic options. Int Immunopharmacol. 2022;113: 109428.CrossRefPubMedPubMedCentral Nazerian Y, Ghasemi M, Yassaghi Y, Nazerian A, Hashemi SM. Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: molecular pathways and potential therapeutic options. Int Immunopharmacol. 2022;113: 109428.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. 2020;382: e38.CrossRefPubMed Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. 2020;382: e38.CrossRefPubMed
10.
Zurück zum Zitat Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574–6.CrossRefPubMed Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574–6.CrossRefPubMed
11.
Zurück zum Zitat Rodriguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114: 102506.CrossRefPubMedPubMedCentral Rodriguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114: 102506.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mantovani Cardoso E, Hundal J, Feterman D, Magaldi J. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020;39:2811–5.CrossRefPubMedPubMedCentral Mantovani Cardoso E, Hundal J, Feterman D, Magaldi J. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020;39:2811–5.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37:217–29.CrossRefPubMed Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37:217–29.CrossRefPubMed
14.
Zurück zum Zitat Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.CrossRefPubMedPubMedCentral Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35–45.CrossRefPubMed Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35–45.CrossRefPubMed
16.
Zurück zum Zitat Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, et al. Patient’s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114:179–88.CrossRefPubMedPubMedCentral Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, et al. Patient’s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114:179–88.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sakaki A, Hosoi H, Kosako H, Furuya Y, Iwamoto R, Hiroi T, et al. Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome. Leuk Lymphoma. 2022;63:2499–502.CrossRefPubMed Sakaki A, Hosoi H, Kosako H, Furuya Y, Iwamoto R, Hiroi T, et al. Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome. Leuk Lymphoma. 2022;63:2499–502.CrossRefPubMed
18.
Zurück zum Zitat Ramos-Casals M, Brito-Zeron P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17:315–32.CrossRefPubMedPubMedCentral Ramos-Casals M, Brito-Zeron P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17:315–32.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105:297–316.CrossRefPubMedPubMedCentral Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105:297–316.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Group WHOREAfC-TW, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518.CrossRefPubMed Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Group WHOREAfC-TW, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518.CrossRefPubMed
23.
Zurück zum Zitat Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20:e276–88.CrossRefPubMedPubMedCentral Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20:e276–88.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39:3037–49.CrossRefPubMedPubMedCentral Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39:3037–49.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–8.CrossRefPubMedPubMedCentral Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–8.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection–United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450–6.CrossRefPubMedPubMedCentral Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection–United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450–6.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Belay ED, Godfred Cato S, Rao AK, Abrams J, Wyatt Wilson W, Lim S, et al. Multisystem inflammatory syndrome in adults after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Clin Infect Dis. 2022;75:e741–8.CrossRefPubMed Belay ED, Godfred Cato S, Rao AK, Abrams J, Wyatt Wilson W, Lim S, et al. Multisystem inflammatory syndrome in adults after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Clin Infect Dis. 2022;75:e741–8.CrossRefPubMed
28.
Zurück zum Zitat Kunal S, Ish P, Sakthivel P, Malhotra N, Gupta K. The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: a systematic review. Heart Lung. 2022;54:7–18.CrossRefPubMedPubMedCentral Kunal S, Ish P, Sakthivel P, Malhotra N, Gupta K. The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: a systematic review. Heart Lung. 2022;54:7–18.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–6.CrossRefPubMed Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–6.CrossRefPubMed
30.
Zurück zum Zitat Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T, Shiota M, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s disease. Pathol Int. 2001;51:671–9.CrossRefPubMed Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T, Shiota M, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s disease. Pathol Int. 2001;51:671–9.CrossRefPubMed
31.
Zurück zum Zitat Oshima K, Kanamori H, Takei K, Baba H, Tokuda K. Severe coronavirus disease 2019 in a patient with TAFRO syndrome: a case report. Clin Infect Pract. 2022;16: 100158.CrossRefPubMedPubMedCentral Oshima K, Kanamori H, Takei K, Baba H, Tokuda K. Severe coronavirus disease 2019 in a patient with TAFRO syndrome: a case report. Clin Infect Pract. 2022;16: 100158.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Yamada M, Sada RM, Kashihara E, Okubo G, Matsushita S, Manabe A, et al. TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report. J Infect Chemother. 2022;28:1008–11.CrossRefPubMedPubMedCentral Yamada M, Sada RM, Kashihara E, Okubo G, Matsushita S, Manabe A, et al. TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report. J Infect Chemother. 2022;28:1008–11.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Nishimura Y, Fajgenbaum DC, Pierson SK, Iwaki N, Nishikori A, Kawano M, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96:1241–52.CrossRefPubMedPubMedCentral Nishimura Y, Fajgenbaum DC, Pierson SK, Iwaki N, Nishikori A, Kawano M, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96:1241–52.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Brito-Zeron P, Melchor S, Seror R, Priori R, Solans R, Kostov B, et al. SARS-CoV-2 infection in patients with primary Sjogren syndrome: characterization and outcomes of 51 patients. Rheumatology (Oxford). 2021;60:2946–57.CrossRefPubMed Brito-Zeron P, Melchor S, Seror R, Priori R, Solans R, Kostov B, et al. SARS-CoV-2 infection in patients with primary Sjogren syndrome: characterization and outcomes of 51 patients. Rheumatology (Oxford). 2021;60:2946–57.CrossRefPubMed
36.
Zurück zum Zitat Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-Garcia A, Tseng LY, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74:766–75.CrossRefPubMedPubMedCentral Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-Garcia A, Tseng LY, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74:766–75.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Fujimoto S, Kawabata H, Kurose N, Kawanami-Iwao H, Sakai T, Kawanami T, et al. Sjogren’s syndrome manifesting as clinicopathological features of TAFRO syndrome: a case report. Medicine (Baltimore). 2017;96: e9220.CrossRefPubMed Fujimoto S, Kawabata H, Kurose N, Kawanami-Iwao H, Sakai T, Kawanami T, et al. Sjogren’s syndrome manifesting as clinicopathological features of TAFRO syndrome: a case report. Medicine (Baltimore). 2017;96: e9220.CrossRefPubMed
38.
Zurück zum Zitat Grange L, Chalayer E, Boutboul D, Paul S, Galicier L, Gramont B, et al. TAFRO syndrome: a severe manifestation of Sjogren’s syndrome? A systematic review Autoimmun Rev. 2022;21: 103137.CrossRefPubMed Grange L, Chalayer E, Boutboul D, Paul S, Galicier L, Gramont B, et al. TAFRO syndrome: a severe manifestation of Sjogren’s syndrome? A systematic review Autoimmun Rev. 2022;21: 103137.CrossRefPubMed
Metadaten
Titel
Severe systemic inflammation mimicking TAFRO syndrome following COVID-19
verfasst von
Misato Tane
Hideki Kosako
Hiroki Hosoi
Kayoko Tabata
Takayuki Hiroi
Kosuke Osawa
Ryuta Iwamoto
Shogo Murata
Toshiki Mushino
Shin-Ichi Murata
Shin-Ichi Araki
Takao Fujii
Takashi Sonoki
Publikationsdatum
31.03.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 3/2023
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03589-9

Weitere Artikel der Ausgabe 3/2023

International Journal of Hematology 3/2023 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.